Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients that are most likely to benefit from their use. We currently have two clinical development programs and one drug discovery program underway: CO-1686, an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is currently the subject of a development program for the treatment of non-small cell lung cancer (NSCLC), in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), currently the subject of a development ... More ...
Analyst Info |
|
| Annual EPS Est: | $-2.86 |
| Quarterly EPS Est: | -0.71 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1.67 |
Data is provided by Zacks Investment Research

